EGb 761 for Mild Cognitive Impairment with Cerebrovascular Disease
Official title: Evaluating the Role of EGb 761 in the Syndrome of Mild Cognitive Impairment With Concomitant Cerebrovascular Disease (MCI + CVD)
Run by National Neuroscience Institute · NCT04525144 · Data updated 2026-11-12
This study is testing if a herbal extract called EGb 761 can help people with Mild Cognitive Impairment and Cerebrovascular Disease improve their thinking and memory over a year.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 45 Years to 85 Years |
| Sex | All |
| Enrollment | 134 (estimated) |
| Sponsor | National Neuroscience Institute Academic / other |
| Locations | 1 site (Singapore) |
| Status | Recruiting |
| Started | October 26, 2020 |
| Main results expected | December 2025 |
| Study ends | November 2026 |
| Registry record updated | November 17, 2022 |
| Trial ID | NCT04525144 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals aged 45 to 85 diagnosed with MCI and CVD, who meet specific cognitive and imaging criteria.
✕Probably not a fit
Patients currently taking antidepressants, antipsychotics, or other specified medications may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the efficacy and safety of EGb 761, a herbal extract, in patients diagnosed with Mild Cognitive Impairment (MCI) who also have Cerebrovascular Disease (CVD). It is an open-label, 52-week trial involving 134 participants, where half will receive the treatment and the other half will serve as a control group. Participants will be assessed based on specific diagnostic criteria and will undergo cognitive evaluations throughout the study. The aim is to provide an alternative treatment option for this patient population by leveraging the neuroprotective properties of EGb 761.
Why it matters
Potential benefit: If successful, this treatment could improve cognitive function and overall clinical outcomes for patients with MCI and CVD.
How similar studies have gone: Previous studies have shown positive outcomes with EGb 761 in cognitive impairment, suggesting potential for success in this specific population.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients who have been diagnosed with MCI based on the Petersen criteria and Albert MS criteria * Patients who have a Global Clinical Dementia Rating Score of 0.5 * Patients aged 45 to 85 years at study entry * Patients who are literate and able to complete the cognitive evaluations in the opinion of the investigators * Patients with the presence of CVD, defined as the presence of white matter hyperintensities (WMH) of Fazekas grade 2 or 3 on MRI brain imaging (done up to 12 months prior to recruitment) or CT scans for patients contraindicated from MRI scans * Patients who provide written informed consent to participate in the study Exclusion Criteria: * Participants should not be receiving antidepressants, antipsychotics, benzodiazepines, acetylcholinesterase inhibitors or NMDA antagonists during the study. Additionally, contraindications for EGb 761 as given in the local prescribing information/Summary of Product Characteristics (SmPC) should be observed.
Where it's running
-
National Neuroscience Institute
Singapore, Singapore Recruiting
Study contacts
- Principal investigator: Kok Pin Ng — National Neuroscience Institute
- Study coordinator: Joanna Wang
- Email: joanna.wang.s@singhealth.com.sg
- Phone: (65) 6357 7635
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Brain recovery after MCA reopening is studied with PET/MR
This study tests how brain blood flow, metabolism, and networks change after reopening a non-acute atherosclerotic middle cerebral artery occlusion in adults receiving recanalization treatment.
-
One-day exercise test to see how brain and body react in epilepsy, cognitive disorders, Parkinson's, dementia, and related conditions
A one-day study tests how an acute bout of exercise changes brain function and bodily signals in people with certain neurological conditions compared with healthy individuals.
-
Choose Myself (Before) Losing Myself
We’re testing an educational interactive booklet to help people with dementia or memory problems think about future medical decisions and start conversations with family or caregivers.
-
NMR-based Risk Test and Digital Health Support for midlife adults in Eloisa
This study tests whether an NMR metabolomics risk test can guide tailored digital health programs for midlife adults at risk of diabetes, heart disease, stroke, kidney disease, or fatty liver.
-
Gut and Oral Microbiome and Cognitive Health in Aging
This study tests whether differences in gut and mouth bacteria are linked to cognitive health in adults across ages and cognitive status.
-
Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns
This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.